EUVIMEDEUVIMED entdecken
Multizentrische Studie

Survival benefit of allogeneic HSCT in CMML patients during the molecular stratification era

Rui Ma, Jin Zhang, Mei-Xiang Zhang, Yuan Li, Yue Yin, Li-Ru Wang, Li Ding, Xiao Lou, Yan-Fang Yu, Lan Ma, Li-Ping Dou, Zhen-Xing Guo und 13 weitere

Cancer Letters · 2026-07 · 649 · 218489

DOI: 10.1016/j.canlet.2026.218489 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Letters, 2026-07. Verfasst von Rui Ma und 24 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myelomonocytic, Chronic. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Peking University, Beijing Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for chronic myelomonocytic leukemia (CMML), yet the population benefit from HSCT and the optimal timing of HSCT remain controversial. Current guidelines, largely based on older CPSS criteria and retrospective data, may not reflect recent advances in transplant techniques and molecular stratification systems. This multicenter retrospective analysis included 389 adult CMML patients from 14 Chinese centers (2015-2023), aiming to reassess the survival benefit of allo-HSCT in a large multicenter cohort within the molecular era. Among all patients, 145 (37.3%) underwent allo-HSCT, including 68.3% from haploidentical donors. Risk stratification was performed using CPSS, MDAPS, CPSS-mol, and MMM systems. Landmark analysis set at day 148 (median transplant interval) was used to assess the effect of time-dependent covariates on long-term survival. The entire cohort had 1-, 3-, and 5-year overall survival (OS) rates of 82.7%, 55.5%, and 46.1%, respectively. In patients ≤70 years, allo-HSCT was associated with significantly improved 3-year OS in CPSS intermediate-1 (63.4% vs. 45.4%, p = 0.038) and intermediate-2 (60.2% vs. 38.7%, p = 0.049), MDAPS intermediate-1 (69.5% vs. 47.4%, p = 0.004), intermediate-2 (60.6% vs. 30.4%, p = 0.029), and high-risk (51.4% vs. 45.0%, p = 0.022), CPSS-mol intermediate-2 (59.8% vs. 39.0%, p = 0.046), and MMM high-risk groups (65.5% vs. 10.5%, p < 0.001). Landmark analysis confirmed sustained benefit in these subgroups. Haploidentical HSCT yielded outcomes comparable to matched donors. Multivariable analysis identified HSCT as an independent favorable factor for survival (HR = 0.619, p = 0.031). These findings advocate expanding transplant eligibility through integration of molecular stratification and modern HSCT platforms, particularly haploidentical protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myelomonocytic, ChronicHumansFemaleMiddle AgedRetrospective StudiesMaleAdultTransplantation, HomologousAgedSurvival RateRisk Assessment

Stichwörter der Autor:innen

Allo-HSCTCMMLHaploidentical HSCTMolecular stratification

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
  • Peking University International Hospital, Beijing, PR China.
  • Peking University First Hospital, Beijing, PR China.
  • Fu Xing Hospital, Beijing, PR China.
  • Air Force Specialty Medical Centre, Beijing, PR China.
  • The Fifth Medical Centre of PLA General Hospital, Beijing, PR China.

Förderung

  • Peking University
  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Ma, R., Zhang, J., Zhang, M. X., Li, Y., Yin, Y., Wang, L. R., Ding, L., Lou, X., Yu, Y. F., Ma, L., Dou, L. P., Guo, Z. X., Ye, F., Wang, Y. N., Liu, Y., Li, L. H., Liu, H. X., Li, N., Jiang, H., …, & Sun, Y. Q. (2026). Survival benefit of allogeneic HSCT in CMML patients during the molecular stratification era. Cancer Letters, 649, 218489. https://doi.org/10.1016/j.canlet.2026.218489

Vancouver

Ma R, Zhang J, Zhang MX, Li Y, Yin Y, Wang LR, et al. Survival benefit of allogeneic HSCT in CMML patients during the molecular stratification era. Cancer Letters. 2026;649:218489. doi:10.1016/j.canlet.2026.218489

BibTeX
@article{Ma2026,
  author = {Ma, Rui and Zhang, Jin and Zhang, Mei-Xiang and Li, Yuan and Yin, Yue and Wang, Li-Ru and Ding, Li and Lou, Xiao and Yu, Yan-Fang and Ma, Lan and Dou, Li-Ping and Guo, Zhen-Xing and Ye, Fang and Wang, Yi-Ni and Liu, Yi and Li, Li-Hong and Liu, Hui-Xin and Li, Na and Jiang, Hao and Jiang, Qian and Zhang, Xiao-Hui and Wang, Yu and Xu, Lan-Ping and Huang, Xiao-Jun and Sun, Yu-Qian},
  title = {Survival benefit of allogeneic HSCT in CMML patients during the molecular stratification era},
  journal = {Cancer Letters},
  year = {2026},
  volume = {649},
  pages = {218489},
  doi = {10.1016/j.canlet.2026.218489}
}
Kostenlos starten →